Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback